Capital Impact Advisors’s Pfizer PFE Stock Holding History

Capital Impact Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-21,868	Closed	-$674K	–	208
2016 Q4	$674K	Hold	21,868	–	–	0.28%	189
2016 Q3	$703K	Hold	21,868	–	–	0.3%	183
2016 Q2	$731K	Buy	+21,868	New	+$698K	0.34%	176

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Impact Advisors's PFE Position: Q1 2017 in Review

Capital Impact Advisors sold out of Pfizer (PFE) in Q1 2017, closing a stake of 21,868 shares — an estimated $674K sold.

Capital Impact Advisors first reported a position in PFE in Q2 2016 and held it in 3 quarters. The position peaked at $731K in Q2 2016. 2,074 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

Capital Impact Advisors reported no remaining Pfizer position as of Q1 2017 after selling out during the quarter.
Capital Impact Advisors sold 21,868 Pfizer shares in Q1 2017, an estimated $674K.
Capital Impact Advisors first reported a position in Pfizer in Q2 2016 and held it in 3 quarters.
Capital Impact Advisors's Pfizer position peaked at $731K in Q2 2016.
2,074 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.